Vogt-Koyanagi-Harada Syndrome in Children: Report of a Case and Review of the Literature

This article reviews the therapeutic approaches in children with Vogt-Koyanagi-Harada (VKH) syndrome, and reports on a 9-year-old girl with progressive visual loss due to VKH syndrome in spite of treatment. In previous reports, corticosteroids were found to be the most effective agents in the treatm...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2007-07, Vol.15 (4), p.351-357
Main Authors: Berker, Nilufer, Ozdamar, Yasemin, Soykan, Emel, Ozdal, Pinar, Ozkan, Seyhan Sonar
Format: Article
Language:English
Subjects:
Child
Corticosteroid
Diagnosis, Differential
Female
Follow-Up Studies
Glucocorticoids - therapeutic use
Humans
Immunosuppressive Agents - therapeutic use
immunosupressives
pediatric uveitis
Recurrence
Retinoscopy
treatment
Uveomeningoencephalitic Syndrome - complications
Uveomeningoencephalitic Syndrome - diagnosis
Uveomeningoencephalitic Syndrome - drug therapy
Vision, Low - etiology
Vision, Low - physiopathology
Visual Acuity
Vogt-Koyanagi-Harada (VKH) syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article reviews the therapeutic approaches in children with Vogt-Koyanagi-Harada (VKH) syndrome, and reports on a 9-year-old girl with progressive visual loss due to VKH syndrome in spite of treatment. In previous reports, corticosteroids were found to be the most effective agents in the treatment of VKH syndrome, while combination therapies with cyclosporine, methotrexate, or azathioprine were used with favorable results in refractory cases. In the current case, none of the treatments sufficiently stabilized the vision, but triple combination of corticosteroids, cyclosporine, and methotrexate suppressed the relapses of intraocular inflammation. Treatment of children with VKH syndrome is challenging. Various treatment modalities have been reported with various responses, but there is still no definite treatment regimen, and the treatment is usually individualized in pediatric VKH cases.
ISSN:0927-3948
1744-5078
DOI:10.1080/09273940701459453